Transformation to AML remains a serious threat for patients with lower-risk MDS4
Almost one-third of patients diagnosed with lower-risk MDS are likely to experience disease progression within 3 years4
In a study with 1914 patients with lower-risk MDS followed up for a median of 16.6 years, 32% of patients progressed to high-risk MDS or experienced AML transformation after a median duration of only 1.8 to 2.4 years.4
Disease progression may lead to shorter overall survival4
patients who experienceD disease progression or AML transformationWERE SHOWN TO HAVE shorter overall survival4
AML, acute myeloid leukemia; MDS, myelodysplastic syndromes.